Status:
COMPLETED
Tifacogin for the Treatment of Patients With Severe Community-Acquired Pneumonia
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Pneumonia
Eligibility:
All Genders
Phase:
PHASE3
Brief Summary
The purpose of this study is to determine whether tifacogin is effective and safe in the treatment of patients with severe community-acquired pneumonia.
Eligibility Criteria
Inclusion
- Diagnosis of community-acquired pneumonia supported by additional clinical, radiological, and microbiological evidence
- Pneumonia of sufficient severity to require ICU admission and management
Exclusion
- Pregnancy
- Weight over 150 kg
- Patients at increased risk of bleeding
- Treatment with drotrecogin alfa or anticipated need for drotrecogin alfa
- Treatment with heparin or anticipated need for heparin
Key Trial Info
Start Date :
May 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2008
Estimated Enrollment :
2136 Patients enrolled
Trial Details
Trial ID
NCT00084071
Start Date
May 1 2004
End Date
July 1 2008
Last Update
December 19 2020
Active Locations (150)
Enter a location and click search to find clinical trials sorted by distance.
1
Mobile, Alabama, United States
2
Loma Linda, California, United States
3
Los Angeles, California, United States
4
Orange, California, United States